Results 1 - 10 of 10 for subject:"glaxosmithkline"
Sorted by Date || Sort by Relevance

March 11, 2009

Biotech, cancer, Inflammation Luke Timmerman wrote: Some members of the band that pumped out a one-hit wonder at Icos are getting back together to see if they can produce at least one more hit at Seattle-based Calistoga Pharmaceuticals. Calistoga has been building up its management team over the pas...
Xconomy [ Feed - Focus - Exclude ] by Luke Timmerman at 10:00 AM | 2 Citations

March 06, 2009

Biotech, cancer, Drugs Luke Timmerman wrote: Nowhere but America makes it possible for a company to pursue its dreams for 28 years without making a profit. Even in the most optimistic times, it’s hard to explain. So how can it possibly be, in the depths of recession, that things are looking up...
Xconomy [ Feed - Focus - Exclude ] by Luke Timmerman at 6:00 AM | 2 Citations

February 13, 2009

The world's second biggest pharmaceutical company is to radically shift its attitude to providing cheap drugs to millions of people in the developing world. In a major change of strategy, the new head of GlaxoSmithKline, Andrew Witty, has told the Guardian he will slash prices on all medicines in th...
Latest news and comment from Britain | guardian.co.uk [ Feed - Focus - Exclude ] by Sarah Boseley at 4:44 PM | 9 Citations

February 09, 2009

Biotech, Drugs, Life Sciences Stewart Lyman wrote: Seattle’s biotech community used to be among the top-ranked in the nation. But as some 2,500 layoffs have piled up in the local biotech sector since 2002, Seattle has tumbled in the rankings. We need to face up to this fact first, before we ca...
Xconomy [ Feed - Focus - Exclude ] by Stewart Lyman at 3:30 AM | 2 Citations

December 16, 2008

Biotech, people, startups Luke Timmerman wrote: It’s cold outside, so I was a little bummed there was no actual fire at an event last night billed as a “fireside chat.” This get-together actually took some time to warm up (pun intended). But once it got rolling, three of the most e...
Xconomy [ Feed - Focus - Exclude ] by Luke Timmerman at 12:10 PM | 4 Citations

December 12, 2008

Biotech, vaccines, Xconomy Luke Timmerman wrote: A newfound energy is coalescing around the science and business of vaccines, and much of it is happening right here in Seattle. We explored the trend yesterday evening in our first Xconomy Forum in Seattle. The event, held at The Institute for Systems...
Xconomy [ Feed - Focus - Exclude ] by Luke Timmerman at 12:00 PM | 1 Citations

May 15, 2008

Treximet, no it is not the feathered T-rex once and for all linking birds to dinosaurs! But it is the last of the triptans to be approved by the FDA before the generics make them extinct. WASHINGTON, DC; May 15th, 2008—Updated May 31st, 2008--Treximet, no it is not the feathered T-rex once and for...
Migraine Blog [ Feed - Focus - Exclude ] at 1:35 PM

April 24, 2008

GlaxoSmithKline is buying a U.S. biotechnology company that is researching resveratrol, the chemical compound found in red wine that may retard the aging process. The CEO of the company says that "drugs that mimic resveratrol, by activating enzymes called sirtuins, could 'treat in a safe, natural ne...
Consumerist [ Feed - Focus - Exclude ] at 2:15 PM

April 23, 2008

The British drug maker said it would acquire a biotechnology company that is pursuing the notion that a compound found in red wine might retard aging....
NYT > Business [ Feed - Focus - Exclude ] at 1:40 AM

March 18, 2008

I recently wrote about the MOTHERS Act and the unnecessary scare tactics surrounding it. A Dallas-Fort Worth TV station picked up on the story and provided a short one-sided view of the issue, continuing to purport that the bill is......
depression introspection [ Feed - Focus - Exclude ] at 5:42 PM
Subscribe to this Search
Get this search in RSS

Add to My Yahoo!
Add to Google
Add to My AOL
Subscribe with Bloglines
Subscribe in NewsGator Online

Mobile
Subscribe on your mobile